EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease

Angelo Armandi, Elisabetta Bugianesi

European Journal of Internal Medicine · 2024-04 · 122 · 20-27

DOI: 10.1016/j.ejim.2024.01.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2024-04. Verfasst von Angelo Armandi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Division of Gastroenterology, University of Turin, Italy. Electronic address: angelo.armandi@unito.it. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) is a disease spectrum encompassing liver injury with progressive severity, tightly connected to the metabolic syndrome. Management of MASLD mostly relies on lifestyle change aiming at improving metabolic homeostasis and insulin resistance. A Mediterranean-like dietary pattern and individualized lifestyle interventions are the cornerstone of MASLD treatment. A careful evaluation of alcohol intake and active treatment of all metabolic co-morbidities are recommended. In the MASLD spectrum, the population with liver inflammation and enhanced fibrogenesis (MASH - Metabolic-dysfunction associated steatohepatitis) can progress to advanced liver disease and has been addressed as "at-risk MASH", eligible to pharmacological treatment according to FDA and EMA. Currently there is a robust therapeutic pipeline across a variety of new targets to resolve MASH or reverse fibrosis, or both. Some of these therapies have beneficial effects that extend beyond the liver, such as effects on glycaemic control, lipid profile and weight loss. For "at-risk" MASH, reversal of fibrosis by one stage or resolution of MASH with no worsening in fibrosis as a surrogate end-point will need to be accompanied by overall survival benefits. In this review, we summarize the current evidence on lifestyle interventions in MASLD as well as pharmacological approaches for fibrosing MASH that have progressed to phase II and phase III clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHumansDietHomeostasisFibrosis

Stichwörter der Autor:innen

Clinical trialsInsulin resistanceLiver fibrosisMediterranean dietMetabolic syndromeMetabolic-dysfunction associated steatotic liver diseaseNon-alcoholic fatty liver diseaseSteatohepatitis

Autor:innen und Institutionen

  • Department of Medical Sciences, Division of Gastroenterology, University of Turin, Italy. Electronic address: angelo.armandi@unito.it.
  • Department of Medical Sciences, Division of Gastroenterology, University of Turin, Italy.

Zitieren

APA

Armandi, A., & Bugianesi, E. (2024). Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. European Journal of Internal Medicine, 122, 20-27. https://doi.org/10.1016/j.ejim.2024.01.005

Vancouver

Armandi A, Bugianesi E. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. European Journal of Internal Medicine. 2024;122:20-27. doi:10.1016/j.ejim.2024.01.005

BibTeX
@article{Armandi2024,
  author = {Armandi, Angelo and Bugianesi, Elisabetta},
  title = {Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  volume = {122},
  pages = {20--27},
  doi = {10.1016/j.ejim.2024.01.005}
}
Kostenlos starten →